Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
16.07
+0.56 (3.61%)
Sep 12, 2024, 4:00 PM EDT - Market closed
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for RNAC stock have an average target of 41.6, with a low estimate of 39 and a high estimate of 45. The average target predicts an increase of 158.87% from the current stock price of 16.07.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RNAC stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 5 | 5 |
| Buy | 1 | 1 | 2 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 5 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +180.02% | Sep 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +180.02% | Sep 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $45 | Strong Buy | Maintains | $49 → $45 | +180.02% | Aug 12, 2024 |
| Needham | Needham | Strong Buy Maintains $42 → $41 | Strong Buy | Maintains | $42 → $41 | +155.13% | Aug 9, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Aug 6, 2024 |
Financial Forecast
Revenue This Year
45.35M
from 26.00M
Increased by 74.40%
Revenue Next Year
13.66M
from 45.35M
Decreased by -69.88%
EPS This Year
-4.75
from -49.80
EPS Next Year
-3.51
from -4.75
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 55.4M | 52.2M | 46.7M | ||
| Avg | 45.4M | 13.7M | 18.1M | ||
| Low | 38.5M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 113.1% | 15.2% | 242.2% | ||
| Avg | 74.4% | -69.9% | 32.2% | ||
| Low | 48.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -4.20 | -1.46 | -1.91 |
| Avg | -4.75 | -3.51 | -4.09 |
| Low | -4.93 | -4.71 | -6.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.